glp-1 agonist consultation process receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease Holding GLP-1 Prior to Colonoscopy:
Description
Tirzepatide was approved in 2022
Long-Term Safety and Efficacy in Adolescents While short-term studies demonstrate the safety and effectiveness of GLP-1, dual, and triple agonists in adolescents, their long-term effects remain largely unknown
Ann Pharmacother (2011) 45:85060
In conclusion, the modifiable risk factors obesity, diabetes, and hypertension increase the risk of COVID-19related mortality in young and middle-aged patients to the level of risk observed in advanced age
